Gilead Sciences (GILD) Stock Secures $7.8B Arcellx Deal — Is This a Buying Opportunity?

TLDR

• On April 28, 2026, Gilead finalized its $7.8 billion purchase of Arcellx, acquiring complete rights to anito-cel, a CAR T-cell therapy for multiple myeloma.
• GILD stock is currently testing an 11-year cup base breakout level at $123.47, with a year-end analyst price target of $173, suggesting a potential 35% increase.
• Although the stock has fallen 8% this month, it has advanced 22% over the last year and is trading near $128.
• The stock’s RSI reading of 27 indicates it is as oversold as it has been in a year, with potential support from the 200-day simple moving average close by.
• The acquisition is anticipated to lower GAAP and non-GAAP diluted EPS for 2026 by $5.57 to $5.67, but is forecast to become accretive starting in 2028, subject to FDA approval.

---

(SeaPRwire) –   Gilead Sciences finalized the Arcellx acquisition on April 28, with a payment of $115 per share in cash and a $5 per share contingent value right. The total equity value at closure was roughly $7.8 billion.

Gilead Sciences, Inc., GILD

This transaction grants Gilead full control of anitocabtagene autoleucel (anito-cel), an investigational BCMA-directed CAR T-cell therapy for multiple myeloma. The two companies were previously partnered through a collaboration agreement involving Kite, Gilead’s cell therapy division.

By fully integrating Arcellx, Gilead removes future obligations for profit-sharing, milestone payments, and royalties. This enables the company to accelerate decisions regarding development and commercialization.

The $5 contingent value right per share will only be paid if cumulative worldwide net sales of anito-cel reach a minimum of $6 billion from its launch through the end of 2029. This is a significant threshold, yet it demonstrates belief in the therapy’s market potential.

Cindy Perettie, the head of Kite at Gilead, stated that the priority is now on “executing with speed and discipline” as the company gets ready to make anito-cel available to patients. Arcellx’s personnel and its D-Domain BCMA binder technology will be incorporated into Kite’s manufacturing and regulatory systems.

Financially, the deal is predicted to decrease Gilead’s 2026 diluted EPS under both GAAP and non-GAAP measures by $5.57 to $5.67. When excluding acquired in-process R&D expenses, the acquisition is expected to be slightly dilutive in 2026 and 2027, then turn accretive from 2028 onwards—contingent on FDA approval for anito-cel.

Arcellx’s common stock will be removed from the Nasdaq Global Select Market after the merger is complete.

Technical Picture

From a technical analysis perspective, GILD is in a notable position. The share price is re-examining an 11-year cup base breakout at a pivot point of $123.47, a pattern originating from bearish candlestick signals in June and July of 2015.

Breakouts over longer timeframes generally have better success probabilities, making this retest significant. The stock’s Relative Strength Index has fallen to 27, a low not witnessed in at least a year, indicating oversold conditions. The 200-day simple moving average is close and previously provided support in May and October of the prior year.

GILD has seen declines in eight of the past ten weeks and is down 8% for April. The pullbacks in both March and April occurred on low trading volume, which some market technicians interpret as a positive signal.

Broader Biotech Context

The SPDR S&P Biotech ETF has gained 9% in 2026, contrasting with a 7% decline in the broader healthcare sector, which is the poorest performer among the 11 major S&P sectors. The iShares Biotechnology ETF, where Gilead is the top holding representing nearly 8% of assets, has a return of less than 1% for the year.

Despite the recent downturn, GILD is up 4% year-to-date and 22% over the past 12 months. A technical analyst has established a year-end price target of $173, which represents a 35% gain from the current price around $128. The bullish outlook remains valid provided the stock stays above $118.

Gilead concluded its tender offer for Arcellx on April 28, with tendered shares accounting for about 77.2% of Arcellx’s outstanding stock.